GenomeKey, Bristol, UK
RAPID ID/AST MACHINE LEARNING & WHOLE GENOME
Diagnostic for Sepsis
GenomeKey (Genomic Labs Ltd.) is developing a rapid diagnostic for sepsis by combining novel bacterial DNA extraction techniques, next generation DNA sequencing and machine learning DNA interpretation. With this, GenomeKey seeks to determine the presence of bacteria in a blood sample, identify the bacterial species and determine its antimicrobial susceptibility, all within a matter of hours, at high accuracy. Current clinical diagnostics for infections, such as sepsis, are fundamentally limited by having to grow bacteria. Due to this, it takes 24-72 hours to determine which antibiotics will effectively treat sepsis, and many test samples fail to yield results.
Current Development Stage: Feasibility
CARB-X Investment: Initial investment of up to $3.0m with potential option payments up to $6.5m.
Initial CARB-X Investment Date: January 1, 2021